Neogen reports Q1 FY2027 revenue growth and raises FY2027 guidance
Neogen Corporation posted Q1 FY2027 revenue of $222.8 million, up 6.5%‑8.1% year over year, and adjusted EBITDA of $41.6 million, an 18.7% margin. The company posted a GAAP loss of $11.9 million but adjusted net income of $17.5 million. Management raised FY2027 revenue guidance to $885 million‑$890 million and adjusted EBITDA guidance to $181 million‑$183 million, citing stronger demand, operational improvements and a pending genomics divestiture.
Why it matters
The raised outlook signals higher expected sales and profitability, which could support the stock price and improve leverage; the company also plans to use proceeds from the genomics sale to reduce debt, aiming for net leverage below 3x (the company says).
Key facts
- 1Q1 FY2027 revenue was $222.8 million finance.yahoo.com
- 2Adjusted EBITDA for the quarter was $41.6 million tradingview.com
- 3GAAP net loss was $11.9 million finance.yahoo.com
- 4Adjusted net income was $17.5 million finance.yahoo.com
- 5FY2027 revenue guidance was raised to $885 million‑$890 million tradingview.com
- 6FY2027 adjusted EBITDA guidance was raised to $181 million‑$183 million tradingview.com
Summary written by AlphAI from 10 of 10 sources. Not investment advice. Figures are as stated by the linked sources.